HeraMED Ltd. (AU:HMD) has released an update.
HeraMED Limited has announced a significant change in Director Anoushka Gungadin’s interests, with the acquisition of 5,000,000 unlisted options at an exercise price of $0.02, expiring in June 2028. This addition complements her existing 850,000 unlisted options, expiring in July 2027, at an exercise price of $0.1358. The change, which involves no immediate financial consideration, signifies a notable shift in the director’s stake in the company.
For further insights into AU:HMD stock, check out TipRanks’ Stock Analysis page.
